What is HC Wainwright’s Forecast for AGIO FY2030 Earnings?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities research analysts at HC Wainwright raised their FY2030 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Thursday, July 30th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will earn $0.66 per share for the year, up from their prior estimate of $0.64. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.33) per share.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada raised their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. JPMorgan Chase & Co. lowered their price objective on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Bank of America increased their target price on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Finally, Truist Financial raised their target price on Agios Pharmaceuticals from $36.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $40.38.

Agios Pharmaceuticals Stock Down 6.5%

NASDAQ:AGIO opened at $32.75 on Friday. The company has a fifty day moving average of $34.45 and a 200 day moving average of $30.89. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The firm has a market capitalization of $1.95 billion, a P/E ratio of -4.52 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. AQR Capital Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 66.8% during the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Agios Pharmaceuticals by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock worth $1,274,000 after buying an additional 2,920 shares during the period. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the 1st quarter worth about $40,000. Goldman Sachs Group Inc. increased its stake in shares of Agios Pharmaceuticals by 16.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock worth $19,299,000 after acquiring an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in Agios Pharmaceuticals during the 1st quarter valued at about $597,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.